Fig. 4

Predictive biomarkers for response to PARP inhibitors. a Volcano plot representation of gene-drug interactions in gynecologic tumors. b Waterfall plot enumerating individual tumor response to olaparib with BRCA1/2 and TP53 mutation status. c Receiver operating characteristic curve plotted for the sensitivity versus 100 - specificity values for predicting olaparib response rates using BRCA1/2 and TP53 mutation status. d Drug response assessment of olaparib on OVISE cell-line that has been stably transduced with/without TP53-R249S, T273H, or R175H mutation. Dose response curves were generated using percent survival of cells under olaparib treatment for 4 days on 9 different doses from 200 to 0.78 μM. P values in a—two-sided Wilcoxon’s rank-sum test, and in c—two-sided binomial exact test